Colin Lightfoot

Colin Lightfoot

B.Sc. Biomedical Science, M.Sc. Infection and Immunity

Colin graduated from the University of Chester with a B.Sc. in Biomedical Science in 2020. Since completing his undergraduate degree, he worked for NHS England as an Associate Practitioner, responsible for testing inpatients for COVID-19 on admission.

See more

Recently Colin was a Study Assistant for Perfectus Biomed, where he grew cell lines and viruses for the testing of mainly commercial cleaning products. He recently completed an M.Sc. in Infection and Immunity at The University of Chester, where his main research focus was antibiotic resistance and the possibility of combatting this with bacteriophage therapy.

See less

Articles from Colin

A clinical tool for monoclonal antibody allocation to treat COVID-19

A clinical tool for monoclonal antibody allocation to treat COVID-19

The zoonotic potential of epidemic porcine deltacoronavirus

The zoonotic potential of epidemic porcine deltacoronavirus

What are the predictors of inpatient COVID-19 mortality rates?

What are the predictors of inpatient COVID-19 mortality rates?

An algorithmic method to identify epidemic waves of COVID-19

An algorithmic method to identify epidemic waves of COVID-19

SARS-CoV-2 shown to spread through cell-to-cell transmission

SARS-CoV-2 shown to spread through cell-to-cell transmission

SARS-CoV-2 spike engagement of ACE2 shown to prime S2′ site cleavage and fusion initiation

SARS-CoV-2 spike engagement of ACE2 shown to prime S2′ site cleavage and fusion initiation

Characteristics of initial hospitalization and readmissions among pediatric patients with COVID-19 in the US

Characteristics of initial hospitalization and readmissions among pediatric patients with COVID-19 in the US

SARS-CoV-2 Omicron belongs to new antigenic cluster compared to all other VOCs

SARS-CoV-2 Omicron belongs to new antigenic cluster compared to all other VOCs

Evaluating the response of lung cancer patients to COVID-19 mRNA vaccination

Evaluating the response of lung cancer patients to COVID-19 mRNA vaccination

Comparison of neutralization of SARS-CoV-2 variants of concern Omicron and Delta

Comparison of neutralization of SARS-CoV-2 variants of concern Omicron and Delta

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.